Downregulation of hsa-miR-132 and hsa-miR-129: non-coding RNA molecular signatures of Alzheimer’s disease

• Published in: Frontiers in Molecular Neuroscience
• Main Authors: Siranjeevi Nagaraj, Carolina Quintanilla-Sánchez, Kunie Ando, Lidia Lopez-Gutierrez, Emilie Doeraene, Andreea-Claudia Kosa, Emmanuel Aydin, Jean-Pierre Brion, Karelle Leroy
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2024-06-01
• Subjects: Alzheimer’s disease (AD); microRNA; miR-132; miR-129; therapeutics
• Online Access: https://www.frontiersin.org/articles/10.3389/fnmol.2024.1423340/full

Alzheimer’s disease (AD) affects the elderly population by causing memory impairments, cognitive and behavioral abnormalities. Currently, no curative treatments exist, emphasizing the need to explore therapeutic options that modify the progression of the disease. MicroRNAs (miRNAs), as non-coding RNAs, demonstrate multifaceted targeting potential and are known to be dysregulated in AD pathology. This mini review focuses on two promising miRNAs, hsa-miR-132 and hsa-miR-129, which consistently exhibit differential regulation in AD. By employing computational predictions and referencing published RNA sequencing dataset, we elucidate the intricate miRNA-mRNA target relationships associated with hsa-miR-132 and hsa-miR-129. Our review consistently identifies the downregulation of hsa-miR-132 and hsa-miR-129 in AD brains as a non-coding RNA molecular signature across studies conducted over the past 15 years in AD research.